Cite
Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
MLA
Lucero, Josephine, et al. “Flow Cytometry-Based Measurable Residual Disease (MRD) Analysis Identifies AML Patients Who May Benefit from Allogeneic Hematopoietic Stem Cell Transplantation.” Annals of Hematology, vol. 103, no. 4, Apr. 2024, pp. 1187–96. EBSCOhost, https://doi.org/10.1007/s00277-024-05639-6.
APA
Lucero, J., Alhumaid, M., Novitzky-Basso, I., Capo-Chichi, J.-M., Stockley, T., Gupta, V., Bankar, A., Chan, S., Schuh, A. C., Minden, M., Mattsson, J., Kumar, R., Sibai, H., Tierens, A., & Kim, D. D. H. (2024). Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 103(4), 1187–1196. https://doi.org/10.1007/s00277-024-05639-6
Chicago
Lucero, Josephine, Muhned Alhumaid, Igor Novitzky-Basso, Jose-Mario Capo-Chichi, Tracy Stockley, Vikas Gupta, Aniket Bankar, et al. 2024. “Flow Cytometry-Based Measurable Residual Disease (MRD) Analysis Identifies AML Patients Who May Benefit from Allogeneic Hematopoietic Stem Cell Transplantation.” Annals of Hematology 103 (4): 1187–96. doi:10.1007/s00277-024-05639-6.